Phase 2 Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People who have been diagnosed (confirmed by tissue or cell testing) with advanced small cell lung cancer (SCLC) at any stage, whose cancer has come back or continued to grow after at least two previous treatments including platinum-based chemotherapy and immunotherapy, or who are unable to tolerate standard second-line treatment
- People diagnosed with a type of lung cancer called large cell neuroendocrine carcinoma (LC NEC), whose cancer has come back or continued to grow after at least one previous treatment
- People with certain neuroendocrine cancers arising outside the lung (such as those from the gut, pancreas, cervix, bladder, or other sites), whose cancer has come back or continued to grow after at least one previous treatment — some of these cancers must have previously tested positive for a protein called DLL3
- People whose cancer shows DLL3 positivity on a specific type of imaging scan (SPECT/CT using a radioactive tracer), as required for certain parts of the trial (confirm with trial site)
- People whose cancer has been confirmed as progressing or returning during or after their most recent treatment, shown on imaging
- People who have at least one area of cancer that can be measured on scans, according to standard criteria
- People whose blood counts and organ function (liver, kidneys, and bone marrow) meet specific minimum levels at the screening stage
- People with cancer that has spread to the brain may still be eligible, as long as their condition is considered clinically stable
Who may not be able to join:
- People with serious ongoing illnesses that are not under control
- People who still have significant side effects from previous cancer treatment, surgery, or radiotherapy that have not resolved to a mild level (with some exceptions for hair loss or stable mild nerve-related symptoms)
- People with active, clinically significant heart disease
- People with a lung condition called interstitial lung disease, or active non-infectious inflammation of the lungs
- People who have had a different type of cancer within the past two years (some exceptions may apply — confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +41 44 755 77 00
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess incidence and severity of safety events following administration of [212Pb]Pb-DOTAM-MAM279; To assess dose modifications of [212Pb]Pb-DOTAM-MAM279; To estimate the maximum tolerated dose (MTD) and/or to define the recommended phase 2 dose (RP2D) for SCLC/LCNEC of the lung and epNECs; To evaluate the preliminary anti-tumor activity of [212Pb]Pb-DOTAM-MAM279 in the dose expansion part
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.